Kynam Capital Management, LP holds a focused book of 36 stocks worth $1.6B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Urogen Pharma Ltd and trimmed Celldex Therapeutics Inc. Their largest long position is Syndax Pharmaceuticals Inc at 12% of the equity book. They also disclosed $21.8M in put options (a bearish bet) and $23.8M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1907884/holdings"
Use Arkolith to show Kynam Capital Management, LP's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
96% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Syndax Pharmaceuticals Inc COM | $188.1M | 8.05M | 11.9% | —Held | |
| 2 | Celldex Therapeutics Inc New COM NEW | $185.3M | 5.84M | 11.8% | ▼−1.7% Reduced · −103K sh | |
| 3 | Vaxcyte Inc COM | $169.8M | 2.92M | 10.8% | —Held | |
| 4 | Cogent Biosciences Inc COM | $155.4M | 4.04M | 9.9% | ▼−35% Reduced · −2.1M sh | |
| 5 | Vera Therapeutics Inc CL A | $136.7M | 3.40M | 8.7% | ▼−1.0% Reduced · −35K sh | |
| 6 | Beam Therapeutics Inc COM | $87.7M | 3.68M | 5.6% | ▲+51% Added · +1.2M sh | |
| 7 | Cytomx Therapeutics Inc. COM | $70.6M | 15.01M | 4.5% | ▲+67% Added · +6.0M sh | |
| 8 | Biocryst Pharmaceuticals Inc COM | $54.1M | 5.68M | 3.4% | ▼−39% Reduced · −3.7M sh | |
| 9 | Travere Therapeutics Inc COM | $46.6M | 1.57M | 3.0% | ▲+203% Added · +1.1M sh | |
| 10 | Viridian Therapeutics Inc COM | $45.8M | 2.34M | 2.9% | ▲+59% Added · +871K sh | |
| 11 | Cullinan Therapeutics Inc COM | $44.3M | 3.11M | 2.8% | —Held | |
| 12 | Urogen Pharma Ltd COM | $40.4M | 2.25M | 2.6% | ▲New New position | |
| 13 | Kalvista Pharmaceuticals Inc COM | $36.7M | 1.82M | 2.3% | ▲+0.6% Added · +10K sh | |
| 14 | Apellis Pharmaceuticals Inc COM | $33.2M | 825.0K | 2.1% | ▼−9.2% Reduced · −84K sh | |
| 15 | Legend Biotech Corp SPONSORED ADS | $28.5M | 1.58M | 1.8% | ▲New New position | |
| 16 | MBX Biosciences Inc COM | $27.9M | 934.8K | 1.8% | —Held | |
| 17 | Immunocore Hldgs PLC ADS | $26.7M | 884.9K | 1.7% | ▲+3.3% Added · +28K sh | |
| 18 | Sutro Biopharma Inc COM SHS | $21.7M | 872.6K | 1.4% | ▲+82% Added · +393K sh | |
| 19 | Burning Rock Biotech Ltd SPONSORED ADS | $19.8M | 1.23M | 1.3% | ▲+23% Added · +233K sh | |
| 20 | Soleno Therapeutics Inc COM | $18.7M | 560.0K | 1.2% | ▲New New position | |
| 21 | Nurix Therapeutics Inc COM | $18.5M | 1.19M | 1.2% | ▼−39% Reduced · −776K sh | |
| 22 | Pharvaris N V COM | $18.1M | 640.4K | 1.1% | —Held | |
| 23 | Evommune Inc COM SHS | $14.4M | 625.5K | 0.9% | ▲+237% Added · +440K sh | |
| 24 | Relay Therapeutics Inc COM | $14.2M | 1.42M | 0.9% | —Held | |
| 25 | Geron Corp COM | $10.2M | 6.84M | 0.6% | ▲+98% Added · +3.4M sh | |
| 26 | Engene Holdings Inc COM | $9.2M | 1.36M | 0.6% | ▼−9.1% Reduced · −136K sh | |
| 27 | Design Therapeutics Inc COM | $8.3M | 784.6K | 0.5% | —Held | |
| 28 | Wave Life Sciences Ltd SHS | $7.0M | 965.2K | 0.4% | ▼−56% Reduced · −1.2M sh | |
| 29 | Climb Bio Inc COM | $6.9M | 1.00M | 0.4% | ▼−2.4% Reduced · −25K sh | |
| 30 | Amarin Corp PLC SPONSORED ADR | $6.8M | 472.4K | 0.4% | ▲+21% Added · +83K sh | |
| 31 | Biohaven Ltd COM | $5.9M | 702.9K | 0.4% | —Held | |
| 32 | Prelude Therapeutics Inc COM | $5.4M | 1.59M | 0.3% | ▲+102% Added · +804K sh | |
| 33 | Caribou Biosciences Inc COM | $4.8M | 2.50M | 0.3% | —Held | |
| 34 | Alector Inc COM | $4.3M | 2.00M | 0.3% | —Held | |
| 35 | Proqr Thrapeutics N V SHS EURO | $2.5M | 1.57M | 0.2% | —Held | |
| 36 | Candel Therapeutics Inc COM | $980K | 200.0K | 0.1% | ▲New New position |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | TRAVERE THERAPEUTICS INCTVTX | $23.8M | 800K |
| PUT · bearish | REVOLUTION MEDICINES INCRVMD | $20.2M | 208K |
| PUT · bearish | TRAVERE THERAPEUTICS INCTVTX | $1.6M | 55K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.